Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGOG-OV5 weekly paclitaxel/carboplatin with prophylactic G-CSF in gynecological cancers
2010-022482-95Phase 2Completed
- Sponsor
- Belgian Gynaecological Oncology Group
- Start
- Nov 2011
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of filgrastim in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 2 more, sponsored by Belgian Gynaecological Oncology Group. Primary endpoint: Prevention of grade 4 neutropenia during chemotherapy. Started Nov 2011; status: completed.
02
Drugs
filgrastim
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Cervical Cancer (CC)endometrial cancer (EC)
Beyond the preview
Go deeper on 2010-022482-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022482-95.